J&J Says New Model-Based Analysis Further Supports The Potential Of Tecvayli Plus Darzalex Faspro

By Reuters News

Sept 23 (Reuters) - Johnson & Johnson JNJ.N:

  • NEW MODEL-BASED ANALYSIS FURTHER SUPPORTS THE POTENTIAL OF TECVAYLI® (TECLISTAMAB-CQYV) PLUS DARZALEX FASPRO® (DARATUMUMAB AND HYALURONIDASE-FIHJ) TO REDEFINE LONG-TERM SURVIVAL EXPECTATIONS IN EARLY LINE RELAPSED/REFRACTORY MULTIPLE MYELOMA

  • J&J - ANALYSIS ESTIMATES 87% OF TECVAYLI PLUS DARZALEX FASPRO PATIENTS HAVE COMPARABLE MORTALITY RISK TO GENERAL POPULATION

  • J&J - TECVAYLI PLUS DARZALEX FASPRO REDUCES MULTIPLE MYELOMA PROGRESSION RISK BY 90% VERSUS STANDARD OF CARE

Further company coverage: JNJ.N

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.